Structure-guided design of AMP mimics that inhibit fructose-1,6- bisphosphatase with high affinity and specificity

Journal of the American Chemical Society

Volumn 129, Issue 50, 2007, Pages 15480-15490

  Erion, Mark D ^a   Dang, Qun ^a   Reddy, M Rami ^a   Kasibhatla, Srinivas Rao ^a,c   Huang, Jingwei ^b   Lipscomb, William N ^b   Van Poelje, Paul D ^a  

^a Metabasis Therapeutics Inc   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; CARBOHYDRATES; DISEASES; ENZYME KINETICS; LIPIDS; METABOLISM; MOLECULAR MODELING; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; BINDING AFFINITY; DESOLVATION ENERGY; PHOSPHONIC ACID; STRUCTURE-GUIDED DESIGN;

ENZYME INHIBITION;

ADENINE; ADENOSINE PHOSPHATE; ALKYL GROUP; ANTIDIABETIC AGENT; BENZIMIDAZOLE; CARBOHYDRATE; ENZYME INHIBITOR; FRUCTOSE BISPHOSPHATASE; GLUCOSE; LIPID; MB 05032; MB 06322; PHOSPHONIC ACID DERIVATIVE; RIBOSE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOHYDRATE METABOLISM; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; DRUG TARGETING; ENERGY EXPENDITURE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; GLUCONEOGENESIS; HYDROPHOBICITY; LIPID METABOLISM; LIVER CELL; MOLECULAR INTERACTION; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REGULATORY MECHANISM; SOLVATION; X RAY CRYSTALLOGRAPHY;

EID: 37849027557     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja074869u     Document Type: Article

References (72)

1. (a) Hardie, D. G. Nature 1994, 370, 599-600.
2. (b) Hardie, D. G.; Hawley, S. A. Bioessays 2001, 23, 1112-1119.
3. (c) Kahn, B. B.; Alquier, T.; Carling, D.; Hardie, D. G. Cell Metab. 2005, 1, 15-25.
4. (d) Hardie, D. G.; Hawley, S. A.; Scott, J. W. J. Physiol. 2006, 574, 7-15.
5. (a) Schrader, J. Circulation 1990, 81, 389-391.
6. (b) Erion, M. D. Annu. Rep. Med. Chem. 1993, 28, 295-304.
7. Hardie, D. G. Rev Endocr. Metab. Disord. 2004, 5, 119-125.
8. (a) Benkovic, S. J.; deMaine, M. M. Adv. Enzymol. Relat. Areas Mol. Biol. 1982, 53, 45-82.
9. (b) Ke, H. M.; Liang, J. Y.; Zhang, Y. P.; Lipscomb, W. N. Biochemistry 1991, 30, 4412-4420.
10. (c) Ke, H. M.; Zhang, Y. P.; Lipscomb, W. N. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 5243-5247.
11. (d) Shyur, L.-F.; Aleshin, A. E.; Honzatko, R. B.; Fromm, H. J. J. Biol. Chem. 1996, 271, 33301-33307.
12. Barford, D.; Hu, S. H.; Johnson, L. N. J. Mol. Biol. 1991, 218, 233-260.
13. (a) DeFronzo, R. A. Diabetes 1988, 37, 667-687.
14. (b) Magnusson, I.; Rothman, D. L.; Katz, L. D.; Shulman, R. G.; Shulman, G. I. J. Clin. Invest. 1992, 90, 1323-1327.
15. (c) Pilkis, S. J.; Granner, D. K. Annu. Rev. Physiol. 1992, 54, 885-909.
16. Hardie, D. G. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 185-210.
17. (a) Choe, J. Y.; Nelson, S. W.; Arienti, K. L.; Axe, F. U.; Collins, T. L.; Jones, T. K.; Kimmich, R. D.; Newman, M. J.; Norvell, K.; Ripka, W. C.; Romano, S. J.; Short, K. M.; Slee, D. H.; Fromm, H. J.; Honzatko, R. B. J. Biol. Chem. 2003, 278, 51176-51183.
18. (b) Wright, S. W.; et al. J. Med. Chem. 2002, 45, 3865-3877.
19. (c) Wright, S. W.; Carlo, A. A.; Danley, D. E.; Hageman, D. L.; Karam, G. A.; Mansour, M. N.; McClure, L. D.; Pandit, J.; Schulte, G. K.; Treadway, J. L.; Wang, I. K.; Bauer, P. H. Bioorg. Med. Chem. Lett. 2003, 13, 2055-2058.
20. (d) Wright, S. W.; Hageman, D. L.; McClure, L. D.; Carlo, A. A.; Treadway, J. L.; Mathiowetz, A. M.; Withka, J. M.; Bauer, P. H. Bioorg. Med. Chem. Lett. 2001, 11, 17-21.
21. (e) Lai, C.; Gum, R. J.; Daly, M.; Fry, E. H.; Hutchins, C.; Abad-Zapatero, C.; von Geldern, T. W. Bioorg. Med. Chem. Lett. 2006, 16, 1807-1810.
22. (f) von Geldern, T. W.; Lai, C.; Gum, R. J.; Daly, M.; Sun, C.; Fry, E. H.; Abad-Zapatero, C. Bioorg. Med. Chem. Lett. 2006, 16, 1811-1815.
23. (a) Kristiansen, M.; Andersen, B.; Iversen, L. F.; Westergaard, N. J. Med. Chem. 2004, 47, 3537-3545.
24. (b) Hoover, D. J.; Lefkowitz-Snow, S.; Burgess-Henry, J. L.; Martin, W. H.; Armento, S. J.; Stock, I. A.; McPherson, R. K.; Genereux, P. E.; Gibbs, E. M.; Treadway, J. L. J. Med. Chem. 1998, 41, 2934-2938.
25. Cool, B.; Zinker, B.; Chiou, W.; Kifle, L.; Cao, N.; Perham, M.; Dickinson, R.; Adler, A.; Gagne, G.; Iyengar, R.; Zhao, G.; Marsh, K.; Kym, P.; Jung, P.; Camp, H. S.; Frevert, E. Cell Metab. 2006, 3, 403-416.
26. Yamanaka, G.; Wilson, T.; Innaimo, S.; Bisacchi, G. S.; Egli, P.; Rinehart, J. K.; Zahler, R.; Colonno, R. J. Antimicrob. Agents Chemother. 1999, 43, 190-193.
27. Gruber, H. E. US Patent 5,658,889, August 19, 1997.
28. (a) Vincent, M. F.; Marangos, P. J.; Gruber, H. E.; Van den Berghe, G. Diabetes 1991, 40, 1259-1266.
29. (b) Vincent, M. F.; Erion, M. D.; Gruber, H. E.; Van den Berghe, G. Diabetologia 1996, 39, 1148-1155.
30. Longnus, S. L.; Wambolt, R. B.; Parsons, H. L.; Brownsey, R. W.; Allard, M. F. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284, R936-R944.
31. van den Berghe, G. PCT Appl. US92/06828.
32. (b) Sullivan, J. E.; Brocklehurst, K. J.; Marley, A. E.; Carey, F.; Carling, D.; Beri, R. K. FEBS Lett. 1994, 353, 33-36.
33. (c) Merrill, G. F.; Kurth, E. J.; Hardie, D. G.; Winder, W. W. Am. J. Physiol. 1997, 273, E1107-E1112.
34. Vincent, M. F.; Bontemps, F.; Van den Berghe, G. Biochem. J. 1992, 281, 267-272.
35. Dang, Q.; Kasibhatla, S. R.; Reddy, M. R.; Jiang, T.; Reddy, K. R.; van Poelje, P. D.; Huang, J.; Lipscomb, W. N.; Erion, M. D. J. Am. Chem. Soc. 2007, 129, 15491-15502.
36. Erion, M. D.; van Poelje, P. D.; Dang, Q.; Kasibhatla, S. R.; Potter, S. C.; Reddy, M. R.; Reddy, K. R.; Jiang, T.; Lipscomb, W. N. Proc. Natl. Acad. Sci. USA. 2005, 102, 7970-7975.
37. van Poelje, P. D.; Potter, S. C.; Chandramouli, V. C.; Landau, B. R.; Dang, Q.; Erion, M. D. Diabetes 2006, 55, 1747-1754.
38. Triscari, J.; Walker, J.; Feins, K.; Tao, B.; Bruce, S. R. Diabetes 2006, 55 (Suppl 1), 444P.
39. (a) Gidh-Jain, M.; Zhang, Y.; van Poelje, P. D.; Liang, J. Y.; Huang, S.; Kim, J.; Elliott, J. T.; Erion, M. D.; Pilkis, S. J.; Raafat el-Maghrabi, M.; Lipscomb, W. N. J. Biol. Chem. 1994, 269, 27732-27738.
40. (b) Iversen, L. F.; Brzozowski, M.; Hastrup, S.; Hubbard, R.; Kastrup, J. S.; Larsen, I. K.; Naerum, L.; Norskov-Lauridsen, L.; Rasmussen, P. B.; Thim, L.; Wiberg, F. C.; Lundgren, K. Protein Sci. 1997, 6, 971-982.
41. (a) Lipscomb, W. N. Unpublished results. The ZMP binding conformation is closely related to the AMP binding conformation found in the human FBPase (ref 21a) and pig kidney FBPase (1FBP, ref 4b) structures,
42. (b) ref 21b.
43. Carboxylic acids were used previously in the design of a series of AMP deaminase inhibitors. High affinity was achieved despite suboptimal interactions in the phosphate binding site by using transition-state mimicry. Erion, M. D.; Srinivas, R. K.; Bookser, B. C.; van Poelje, P. D.; Reddy, M. R.; Gruber, H. E.; Appleman, J. R. J. Am. Chem. Soc 1999, 121, 308-319.
44. (a) Erion, M. D.; van Poelje, P. D.; Reddy, M. R. J. Am. Chem. Soc. 2000, 122, 6114-6115.
45. (b) Reddy, M. R.; Erion, M. D. J. Am. Chem. Soc. 2001, 123, 6246-6252.
46. (c) Reddy, M. R.; Erion, M. D. In Free Energy Calculations in Rational Drug Design; Reddy, M. R., Erion, M. D., Eds.; Kluwer/Plenum Press: New York, 2001; pp 285-297.
47. (d) Reddy, M. R.; Erion, M. D. J. Am. Chem. Soc. 2007, 129, 9296-9297.
48. Chang, C. A.; Chen, W.; Gilson, M. K. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 1534-1539.
49. Connolly, M. L. Science 1983, 221, 709-713.
50. Dang, Q.; Brown, B. S.; Erion, M. D. Tetrahedron Lett. 2000, 41, 6559-6562.
51. Pesin, V. G.; D'yachenko, S. A.; Khaletskii, A. M. J. Gen. Chem., USSR (Eng. Transt.), 1964, 34, 3807-3812.
52. (a) Zwanzig, R. J. J. Chem. Phys. 1954, 22, 1420-1426.
53. (b) Tembe, B. L.; McCammon, J. A. Comput. Chem. 1984, 8, 281-283.
54. (c) Pearlman, D. A. In Free Energy Calculations in Rational Drug Design; Reddy, M. R., Erion, M. D., Eds.; Kluwer/Plenum Press: New York, 2001; pp 9-35.
55. (a) Singh, U. C.; Benkovic, S. J. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 9519-9523.
56. (b) Reddy, M. R.; Viswanadhan, V. N.; Weinstein, J. N. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 10287-10291.
57. (c) Reddy, M. R.; Bacquet, R. J.; Zichi, D.; Mathews, D. A.; Welsh, K. M.; Jones, T. R.; Freer, S. J. Am. Chem. Soc. 1992, 114, 10117-10122.
58. Saenger, W. In Principles of Nucleic Acid Structure; Cantor, C. R., Ed.; Springer-Verlag: New York, 1984; pp 51-104.
59. (a) Moodie, S. L.; Mitchell, J. B.; Thornton, J. M. J. Mol. Biol. 1996, 263, 486-500.
60. (b) Moodie, S. L.; Thornton, J. M. Nucleic Acids Res. 1993, 21, 1369-1380.
61. van Montfoort, J. E.; Hagenbuch, B.; Groothuis, G. M.; Koepsell, H.; Meier, P. J.; Meijer, D. K. Curr. Drug Metabol. 2003, 4, 185-211.
62. The order of reagent addition and addition times are critical for successful conversion. The addition of acetic acid before the reducing agent results in exclusive formation of the dihydrobenzimidazole.
63. An exotherm was observed during the iron (III) chloride addition.
64. (a) Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagoha, G.; Profeta, S., Jr.; Weiner, P. K. J. Am. Chem. Soc. 1984, 106, 765-784.
65. (b) Singh, U. C.; Weiner, P. K.; Caldwell, J. K.; Kollman, P. A. AMBER Version 3.0; University of California at San Francisco: San Francisco, CA, 1986.
66. (a) Berendsen, H. J. C.; Grigera, J. R.; Straatsma, T. P. J. Phys. Chem. 1987, 91, 6269-6271.
67. (b) Reddy, M. R.; Berkowitz, M. J. Chem. Phys. 1988, 88, 7104-7110.
68. Reddy, M. R.; Erion, M. D.; Agarwal, A. In Reviews in Computational Chemistry; Lipkowitz, K. B., Boyd, D. B., Eds.; Wiley-VCH: New York, 2000; Vol. 16, pp 217-304.
69. Navaza, J. Acta Cryst. 1994, A50, 157-163.
70. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, N.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Acta Cryst. 1998, D54, 905-921.
71. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Acta Cryst. 1991, A47, 110-119.
72. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. J. App. Cryst. 1993, 26, 283-291.